Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Category Primary study
JournalBLOOD
Year 2019
This article has no abstract
Epistemonikos ID: 5625b8344a15f93dde6e83461d8fa234d2475a67
First added on: Feb 11, 2025